HomeGeneticsConditionMcCune-Albright syndrome
Back to Condition
McCune-Albright syndrome
Reviewed by Medicinsk Expert•Last updated: 2026-10-22•Condition

McCune-Albright syndrome

McCune-Albright syndrome is a complex disorder affecting the bones, skin, and endocrine system, caused by random genetic mutations that occur early in development.

Overview

This syndrome is characterized by polyostotic fibrous dysplasia, where bone is replaced by fibrous scar-like tissue, often on one side of the body. This can lead to fractures, deformities, and asymmetric growth of the skull, jaw, or limbs. Affected individuals also typically present with light brown skin patches known as café-au-lait spots, which often feature irregular borders compared to those seen in other conditions.

Endocrine Involvement

The syndrome frequently causes hormone-related issues, including:

  • Precocious puberty: Early onset of menstruation, sometimes as early as age 2, due to excess estrogen.
  • Thyroid issues: Enlargement of the thyroid (goiter) or nodules, often leading to hyperthyroidism.
  • Growth hormone excess: Can lead to acromegaly, characterized by large hands and feet, arthritis, and facial changes.
  • Cushing syndrome: Rarely, an excess of cortisol occurs, typically before age 2.

Causes & Inheritance

McCune-Albright syndrome is caused by a mutation in the GNAS gene, which leads to the constant activation of the adenylate cyclase enzyme. This condition is not inherited; it results from a random mutation occurring early in development, leading to mosaicism, where only some of the body's cells carry the mutation. Because the mutation is not present in every cell, it is not passed to the next generation.

Frequently Asked Questions

Weight‑bearing activities should be limited to low‑impact exercises (e.g., swimming, cycling). Calcium (1,000–1,200 mg/day) and vitamin D (800–1,000 IU/day) supplementation support bone health. Bisphosphonates (e.g., intravenous pamidronate) can decrease bone pain and turnover, but they do not reverse lesions. Orthopedic surgery is considered for deformities causing functional impairment, recurrent fractures, or severe limb length discrepancy; intramedullary rodding often provides the most durable stabilization.
MAS spots are typically large (>5 cm), have “coast‑of‑California” (irregular, jagged) borders, and follow a segmental (blotchy) distribution. In neurofibromatosis type 1, spots are usually smaller, have smooth “coast‑of‑Maine” borders, and are often accompanied by axillary freckling, neurofibromas, or Lisch nodules. A dermatologist can perform a skin exam and, if needed, genetic testing for NF1 to confirm.
Baseline and annual assessments should include: serum calcium, phosphate, alkaline phosphatase (bone turnover); thyroid function tests (TSH, free T4); fasting glucose and insulin; cortisol (midnight salivary or 24‑hour urinary); growth hormone (IGF‑1) and prolactin; and sex steroids (estradiol or testosterone). If any values are abnormal, repeat testing every 3–6 months and refer to the appropriate subspecialist (endocrinology, orthopedics, ophthalmology).
First‑line therapy is a GnRH agonist (e.g., leuprolide) given as a depot injection every 1–3 months, which suppresses gonadotropin release. Aromatase inhibitors (e.g., anastrozole) or selective estrogen receptor modulators can be added if estrogen remains high. Common side effects include injection site pain, hot flashes, and temporary slowed growth; long‑term monitoring of bone age and height velocity is essential.
Source: MedlinePlus, National Library of Medicine

MedlinePlus brings together authoritative health information from the National Library of Medicine (NLM), the National Institutes of Health (NIH), and other government agencies and health-related organizations.

Meyahealth

Ⓒ 2026. All rights reserved by MEYA